-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the State Council’s policy briefing was held on the progress of deepening the reform of centralized procurement of medicines and high-value medical consumables.
The promotion of centralized procurement and expansion was mentioned again.
Among them, drug balloons have become one of the key varieties of high-value medical consumables centralized procurement.
one
.
Drug balloon is an important consumable in cardiology.
As a new interventional treatment device, drug balloon has been confirmed by many clinical trials for its efficacy in various coronary stenosis lesions, small vessel lesions, bifurcation lesions, etc.
and security
.
Previously, the use of cardiac stents increased after the price reduction through centralized procurement, and at the same time, the use of drug balloons also increased significantly
.
However, because the drug balloon is not included in the centralized collection, the price is inflated
.
According to the data of GF Securities Development Research Center, the import unit price of drug balloons was about 25,000 yuan, and the domestic single price was about 20,000 yuan
.
It is understood that in 2021, Jiangsu and other places have already carried out the practice of centralized procurement of drug balloons, and this year, it will be expanded to the whole country to block the space of inflated prices
.
The author learned that, at present, the global drug balloon market is still dominated by foreign companies such as Braun, Medtronic, Boston Scientific, but at the same time, many local companies are also making arrangements, such as Xianruida, Yinyi Biology, Grand Pharmaceutical, Cardiovascular Medical, Lepu Medical, Xinzhi Medical, Xinlitai, Sino Medical,
etc.
For example, according to Sino Medical's 2021 semi-annual report, Sino Medical's main products include coronary drug stent systems, coronary balloon dilation catheters, and intracranial balloon dilation catheters
.
The performance forecast shows that the company's intracranial balloon products will continue to maintain steady growth in 2021
.
According to Litai's announcement, MA company was established in 2008, mainly engaged in the research and development and production of high-end cardiovascular interventional medical devices.
Its core product is "Rapamycin Drug Eluting Balloon Selution", which has independent knowledge on a global scale Property rights, which can be used to treat coronary artery disease or peripheral artery disease,
etc.
In 2018, Xinlitai signed an "Exclusive License Agreement" with MA to obtain the intellectual property and technical information related to "Rapamycin Drug Eluting Balloon Selution" owned by it with its own funds of 10 million US dollars. .
According to the data, Lepu Medical has certified drug stents (Partner/GuReater/Nano metal drug stent, NeoVas fully absorbable drug stent), drug balloon (Paclitaxel drug balloon Vesselin), drug balloon (Paclitaxel drug balloon Vesselin), Cutting balloon (Vesscide) and interventional accessories (guide wire/catheter/sheath/Y valve/pressure pump/compressor/syringe), as well as interventional non-implanted balloons (coronary small vessels/ACS/original) position drug balloon, third-generation rapamycin drug balloon)
.
In addition, the data shows that the coronary drug balloon Qingzhou drug balloon developed by Yinyi Bio was approved for marketing in December 2017; in 2019, the drug balloon developed by Shenqi Medical was approved for marketing, and in 2020, including Yuanda Pharmaceutical and A number of domestic drug balloons, such as coronary drug balloons independently developed in cooperation with German affiliates, peripheral drug balloons from Cardiovascular Medicine, and Vesselin, a coronary drug balloon from Lepu Medical, have been approved
.
The technology of drug balloon provides a new treatment option for coronary atherosclerotic cardiovascular disease and is an important consumable in cardiology department
.
The industry predicts that the compound annual growth rate of China's drug balloon market will remain at 13.
8%.
By 2021, the market size is expected to reach 8.
38 billion yuan, and the potential market size may exceed 10 billion yuan
.
With the development of centralized procurement, the utilization rate of drug balloons is expected to increase significantly, and the concept of "intervention without implantation" will be further promoted
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The promotion of centralized procurement and expansion was mentioned again.
Among them, drug balloons have become one of the key varieties of high-value medical consumables centralized procurement.
one
.
Drug balloon is an important consumable in cardiology.
As a new interventional treatment device, drug balloon has been confirmed by many clinical trials for its efficacy in various coronary stenosis lesions, small vessel lesions, bifurcation lesions, etc.
and security
.
Previously, the use of cardiac stents increased after the price reduction through centralized procurement, and at the same time, the use of drug balloons also increased significantly
.
However, because the drug balloon is not included in the centralized collection, the price is inflated
.
According to the data of GF Securities Development Research Center, the import unit price of drug balloons was about 25,000 yuan, and the domestic single price was about 20,000 yuan
.
It is understood that in 2021, Jiangsu and other places have already carried out the practice of centralized procurement of drug balloons, and this year, it will be expanded to the whole country to block the space of inflated prices
.
The author learned that, at present, the global drug balloon market is still dominated by foreign companies such as Braun, Medtronic, Boston Scientific, but at the same time, many local companies are also making arrangements, such as Xianruida, Yinyi Biology, Grand Pharmaceutical, Cardiovascular Medical, Lepu Medical, Xinzhi Medical, Xinlitai, Sino Medical,
etc.
For example, according to Sino Medical's 2021 semi-annual report, Sino Medical's main products include coronary drug stent systems, coronary balloon dilation catheters, and intracranial balloon dilation catheters
.
The performance forecast shows that the company's intracranial balloon products will continue to maintain steady growth in 2021
.
According to Litai's announcement, MA company was established in 2008, mainly engaged in the research and development and production of high-end cardiovascular interventional medical devices.
Its core product is "Rapamycin Drug Eluting Balloon Selution", which has independent knowledge on a global scale Property rights, which can be used to treat coronary artery disease or peripheral artery disease,
etc.
In 2018, Xinlitai signed an "Exclusive License Agreement" with MA to obtain the intellectual property and technical information related to "Rapamycin Drug Eluting Balloon Selution" owned by it with its own funds of 10 million US dollars. .
According to the data, Lepu Medical has certified drug stents (Partner/GuReater/Nano metal drug stent, NeoVas fully absorbable drug stent), drug balloon (Paclitaxel drug balloon Vesselin), drug balloon (Paclitaxel drug balloon Vesselin), Cutting balloon (Vesscide) and interventional accessories (guide wire/catheter/sheath/Y valve/pressure pump/compressor/syringe), as well as interventional non-implanted balloons (coronary small vessels/ACS/original) position drug balloon, third-generation rapamycin drug balloon)
.
In addition, the data shows that the coronary drug balloon Qingzhou drug balloon developed by Yinyi Bio was approved for marketing in December 2017; in 2019, the drug balloon developed by Shenqi Medical was approved for marketing, and in 2020, including Yuanda Pharmaceutical and A number of domestic drug balloons, such as coronary drug balloons independently developed in cooperation with German affiliates, peripheral drug balloons from Cardiovascular Medicine, and Vesselin, a coronary drug balloon from Lepu Medical, have been approved
.
The technology of drug balloon provides a new treatment option for coronary atherosclerotic cardiovascular disease and is an important consumable in cardiology department
.
The industry predicts that the compound annual growth rate of China's drug balloon market will remain at 13.
8%.
By 2021, the market size is expected to reach 8.
38 billion yuan, and the potential market size may exceed 10 billion yuan
.
With the development of centralized procurement, the utilization rate of drug balloons is expected to increase significantly, and the concept of "intervention without implantation" will be further promoted
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
